Mitesh J Borad, MD

Associate Professor

  • 3648 Citations
  • 22 h-Index
20032019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 11 Similar Profiles
Neoplasms Medicine & Life Sciences
Cholangiocarcinoma Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Pancreatic Neoplasms Medicine & Life Sciences
Maximum Tolerated Dose Medicine & Life Sciences
Safety Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Receptor, Fibroblast Growth Factor, Type 2 Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2003 2019

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma

Zakharia, K., Miyabe, K., Wang, Y., Wu, D., Moser, C. D., Borad, M. J. & Roberts, L. R., Jan 1 2019, In : Translational Oncology. 12, 1, p. 143-153 11 p.

Research output: Contribution to journalArticle

Casein Kinase II
Cholangiocarcinoma
gemcitabine
Cisplatin
Heterografts
2 Citations

Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study)

Bergquist, J. R., Shah, H. N., Habermann, E. B., Hernandez, M. C., Ivanics, T., Kendrick, M. L., Smoot, R. L., Nagorney, D. M., Borad, M. J., Mc Williams, R. R. & Truty, M., Apr 1 2018, In : International Journal of Surgery. 52, p. 171-179 9 p.

Research output: Contribution to journalArticle

Gallbladder Neoplasms
Cohort Studies
Retrospective Studies
Adjuvant Chemotherapy
Gallbladder

A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

Mody, K., Mansfield, A., Vemireddy, L., Nygren, P., Gulbo, J. & Borad, M. J., Jan 1 2018, (Accepted/In press) In : Investigational New Drugs.

Research output: Contribution to journalArticle

Iron Chelating Agents
Chelating Agents
Iron
Clinical Trials
Safety

Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma

Kommalapati, A., Tella, S. H., Goyal, G., Borad, M. J., Alberts, S. R., Roberts, L. R., Hubbard, J. M., Durgin, L., Cleary, S. & Mahipal, A., Jan 1 2018, (Accepted/In press) In : HPB.

Research output: Contribution to journalArticle

Cholangiocarcinoma
Survival
Liver
Therapeutics
Insurance

Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples

Vasmatzis, G., Wang, X., Smadbeck, J. B., Murphy, S. J., Geiersbach, K. B., Johnson, S. H., Gaitatzes, A. G., Asmann, Y., Kosari, F., Borad, M. J., Serie, D. J., McLaughlin, S. A., Kachergus, J. M., Necela, B. M. & Thompson, E. A., Jul 13 2018, In : BMC Cancer. 18, 1, 738.

Research output: Contribution to journalArticle

Chromosomes, Human, Pair 8
Breast Neoplasms
Chromosomes, Human, Pair 17
Transcriptome
Genome